A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-In-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
posted on 2022-01-11, 12:48authored byAdis Journals on behalf of, Dominic Brittain, Peter D’Andrea, Emilie Gruen, Motoi Hosoe, Devendra JainDevendra Jain, Juergen Jauernig, Abhijit Pethe, Emil Scosyrev, Ana-Maria Tanase, Hanns-Christian Tillman
Article full
text
The above talking head video represents the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite).